Bladder cancer recurrence and mortality could decline with better treatment compliance

June 5, 2013 by Shaun Mason

(Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie have found that more intense surveillance and treatment of bladder cancer in the first two years after diagnosis could reduce the number of patients whose cancer returns after treatment and lower the disease's death rate. The study was published online ahead of press today in the journal Cancer.

Based on the team's previous research showing underutilization of care for patients with bladder cancer, this study is the first to examine the burden of the disease on the population. To date no one had examined the morbidity of of the disease in the U.S.

Chamie, assistant professor-in-residence in the UCLA department of urology, and his colleagues found that nearly three quarters of patients with high-grade, non–muscle-invasive bladder cancer suffered a return of the disease within 10 years. In 33 percent of patients, the cancer progressed to a more advanced form requiring removal of the bladder, or systemic chemotherapy. And in an additional 41 percent, the cancer recurred without further spread of the disease.

"Even though 80 percent of bladder cancer patients don't die of their disease within five years, most patients will either die of other causes or bladder cancer, require —removal of the bladder, radiation and/or chemotherapy—or have a recurrence of the disease," Chamie said. "This study highlights the need to comply with treatment guidelines to prevent recurrences by instilling inside the bladder and following patients more closely within the first two years of diagnosis."

The study was based on a nationwide sample of who had high-grade, non–muscle-. "We have Level I evidence that demonstrates that a single instillation of chemotherapy into the bladder can minimize recurrences, and that six instillations can minimize recurrence and progression," Chamie said. "Efforts should be increased to offer patients intravesical therapy with the goal of minimizing the burden of this disease."

The researchers also found that the burden of bladder cancer on the population is very high, and that the elderly, women and African-American patients had a higher likelihood of dying of bladder cancer than younger patients, men and white patients, respectively.

Explore further: Certain bladder-cancer patients may be at high risk of disease recurrence despite bladder removal

Related Stories

Certain bladder-cancer patients may be at high risk of disease recurrence despite bladder removal

May 7, 2013
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests.

Genetic alterations linked with bladder cancer risk, recurrence, progression, and patient survival

March 25, 2013
A new analysis has found that genetic alterations in a particular cellular pathway are linked with bladder cancer risk, recurrence, disease progression, and patient survival. Published early online in Cancer, a peer- reviewed ...

Key find for early bladder cancer treatment

May 23, 2013
Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

Bladder cancer patients over 70 less likely to get curative treatment

April 17, 2013
(Medical Xpress)—Older bladder cancer patients are less likely than younger patients to receive treatments intended to cure their disease such as surgery to remove the bladder or radiotherapy. But this difference cannot ...

Low-risk bladder cancer rarely progresses to muscle invasion

March 6, 2013
(HealthDay)—Low-risk bladder cancer rarely progresses to muscle invasion but is associated with an increased risk of disease-specific mortality compared with matched populations, according to research published in the March ...

Nearly all patients with high-grade bladder cancer do not receive guideline-recommended care

July 11, 2011
A study at UCLA's Jonsson Comprehensive Cancer Center found that nearly all patients with high-grade, non-invasive bladder cancer are not receiving the guideline-recommended care that would best protect them from recurrence, ...

Recommended for you

Team identifies a switch that may help target dormant cancer cells

September 26, 2017
A study by scientists at the University of Arizona and the University of Pittsburgh may hold the key to targeting dormant—or inactive —cancer cells, which are resistant to chemotherapy and other treatments. The results ...

Researchers discover how enzyme 'shape-shifts' in drug-resistant leukemia

September 26, 2017
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Cancer vaccines need to target T cells that can persist in the long fight against cancer

September 25, 2017
Cancer vaccines may need to better target T cells that can hold up to the long fight against cancer, scientists report.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.